HURA

Tuhura Biosciences, Inc. (HURA) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2025. Tuhura Biosciences, Inc. is a clinical-stage immuno-oncology company focused on developing personalized cancer vaccines and antibody-drug conjugates to overcome resistance to immunotherapies. The company operates as a non-accelerated filer and smaller reporting company. As of May 12, 2025, there were 43,680,396 shares of common stock outstanding.

Key Financial Metrics

Debt and Liquidity: The company has no long-term debt as of March 31, 2025. Current liabilities consist primarily of accounts payable and accrued expenses ($4.6 million). The company holds approximately $6.2 million in cash, with management projecting sufficiency to fund operations into the late fourth quarter of 2025, excluding funds required for the Kineta merger.

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses rose by $2.4 million to $7.0 million. Research and Development (R&D) expenses increased by $1.0 million to $4.6 million, driven by a $1.0 million increase in personnel and facility costs, partially offset by a decrease in direct costs for the IFx-2.0 program. General and Administrative (G&A) expenses more than doubled to $2.4 million, attributed to higher stock-based compensation, merger transaction costs, and public company compliance costs.
• Grant Income: The company recognized $252,554 in grant income in Q1 2025, compared to none in Q1 2024, related to a Business Innovation Research grant assumed in the Kintara Merger.
• Elimination of Interest Expense: Interest expense of $255,122 recorded in Q1 2024 was eliminated in Q1 2025 following the conversion of TuHURA Notes into common stock during the Kintara Merger.
• Investing Activities: The company utilized $1.2 million in cash for investing activities, primarily for deposits and advances related to the planned acquisition of Kineta, Inc.

Guidance, Outlook, and Risks

Merger with Kineta, Inc.: The company is pursuing a merger with Kineta, Inc., expected to close in Q2 2025. A critical condition precedent is the completion of a financing event raising at least $20 million in gross proceeds. The merger consideration includes a base cash amount of approximately $6 million and up to ~4 million shares of Tuhura common stock.

Clinical Outlook: Tuhura plans to initiate a Phase 3 trial for its lead candidate, IFx-2.0, in Q2 2025. A Phase 1b/2a study for IFx-2.0 was initiated on May 5, 2025.

Liquidity and Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months without additional financing. The company expects to raise capital through equity offerings, debt, or partnerships.

Risks:

• Regulatory Uncertainty: Significant risks exist regarding FDA workforce reductions and budget cuts announced in early 2025, which could delay clinical trial reviews and approvals.
• Trade and Tariffs: New U.S. tariffs on imports from China, Canada, and Mexico could increase manufacturing and sourcing costs.
• Financing Risk: Failure to secure the required $20 million financing would prevent the Kineta merger from closing.

Key Facts for Investor Verification

• Merger Financing Condition: Verify the status of the required $20 million financing event necessary to close the Kineta merger.
• Warrant Exercise Notes: Confirm the repayment of $3.0 million in Warrant Exercise Notes due on May 30, 2025, which are currently recorded as "Due from stockholders."
• Phase 3 Trial Initiation: Monitor the timeline for the initiation of the IFx-2.0 Phase 3 trial, currently targeted for Q2 2025, and any FDA regulatory holds.
• Cash Burn Rate: Assess the sustainability of the current cash position ($6.2 million) against the projected burn rate and the timeline for the next capital raise.
• Executive Departure: Review the impact of the separation of former Chief Scientific Officer Dennis Yamashita (effective Dec 2024) on ongoing R&D programs.